Law360 (April 18, 2018, 12:05 PM EDT) — On March 28, 2018, the U.K. Court of Appeal handed down its decision in Regeneron Pharmaceuticals Inc. v. Kymab Ltd. and Novo Nordisk AS,[1] reversing a lower court decision that found two critical patents covering Regeneron’s transgenic mice technology …
